Caricamento...
Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis
BACKGROUND: In CARE-MS II (Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis; NCT00548405), alemtuzumab (12 mg/day; baseline: 5 days; 12 months later: 3 days) significantly improved health-related quality of life (HRQL) outcomes versus subcutaneous interferon beta-1a (SC IFNB-1a)...
Salvato in:
| Pubblicato in: | Mult Scler |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7350196/ https://ncbi.nlm.nih.gov/pubmed/31144568 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458519849796 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|